Filing Details
- Accession Number:
- 0001567619-20-021489
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-22 16:10:16
- Reporting Period:
- 2020-12-21
- Accepted Time:
- 2020-12-22 16:10:16
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1437402 | Ardelyx Inc. | ARDX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1611193 | W Jeffrey Jacobs | C/O Ardelyx, Inc. 34175 Ardenwood Blvd, Suite 200 Fremont CA 94555 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-12-21 | 3,949 | $6.88 | 92,862 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 17, 2020.
- This transaction was executed in multiple trades in prices ranging from $6.76 to $7.04, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.